Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (331-340 of 377) with videos related to

Pageof 38
Sort By:
The British Journal of Dermatology|January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Journal of the American Academy of Dermatology|July 7, 2026
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension studyAlan D Irvine, Amy S Paller, Elaine C Siegfried, et al.
Pediatric Dermatology|June 26, 2023
Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosaMargaret E Scollan, Laura E Levin, Anne W Lucky, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
JAMA Dermatology|February 24, 2021
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric PatientsCarmen Liy-Wong, Mary Kim, A Yasmine Kirkorian, et al.
JAMA Dermatology|May 18, 2017
Pediatric Psoriasis Comorbidity Screening GuidelinesEmily Osier, Audrey S Wang, Megha M Tollefson, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pediatric Dermatology|December 29, 2022
Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patientsSneha Rangu, Jessica Collins, Maria Teresa García-Romero, et al.
JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
Pageof 38

Showing results (331-340 of 377) with videos related to

Sort By:
Pageof 38
The British Journal of Dermatology|January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Journal of the American Academy of Dermatology|July 7, 2026
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension studyAlan D Irvine, Amy S Paller, Elaine C Siegfried, et al.
Pediatric Dermatology|June 26, 2023
Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosaMargaret E Scollan, Laura E Levin, Anne W Lucky, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
JAMA Dermatology|February 24, 2021
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric PatientsCarmen Liy-Wong, Mary Kim, A Yasmine Kirkorian, et al.
JAMA Dermatology|May 18, 2017
Pediatric Psoriasis Comorbidity Screening GuidelinesEmily Osier, Audrey S Wang, Megha M Tollefson, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pediatric Dermatology|December 29, 2022
Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patientsSneha Rangu, Jessica Collins, Maria Teresa García-Romero, et al.
JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
Pageof 38